A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Hsieh, Ming Hong ^a   Lin, Wei Wen ^b,c   Chen, Shao Tsu ^d   Chen, Kao Ching ^e   Chen, Kuang Peng ^f   Chiu, Nan Ying ^g   Huang, Chao ^h   Chang, Ching Jui ⁱ   Lin, Cheng Hsiu ^j   Lai, Te Jen ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c Peaceful Mind Psychiatry Clinic   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h Wei Gong Memorial Hospital   (Taiwan)

ⁱ CATHAY GENERAL HOSPITAL   (Taiwan)

^j Catholic Mercy Hospital Hsinchu   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL; GLUCOSE; HALOPERIDOL; LIPID; LORAZEPAM; LOXAPINE SUCCINATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE;

ABDOMINAL DISTENSION; ADULT; AGED; AGGRESSION; AGITATION; AKATHISIA; ARTICLE; AUDITORY HALLUCINATION; BLURRED VISION; BODY MASS; BODY WEIGHT; CAREGIVER; CLINICAL TRIAL; CONSTIPATION; DISORIENTATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; IMPULSE CONTROL DISORDER; INSOMNIA; IRRITABILITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PARANOIA; PERSECUTORY DELUSION; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYNCOPE; TAIWAN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 77957338360     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-35     Document Type: Article

References (30)

1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, . Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688, 16172203, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
2. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 2005, 56:273-282. 10.1176/appi.ps.56.3.273, 15746501.
3. American Psychiatric Association Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 2004, 161:1-56. 2, American Psychiatric Association.
4. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002, 302:381-389. 10.1124/jpet.102.033175, 12065741.
5. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003, 28:1400-1411.
6. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004, 483:45-53. 10.1016/j.ejphar.2003.10.025, 14709325.
7. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002, 441:137-140. 10.1016/S0014-2999(02)01532-7, 12063084.
8. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004, 18:375-383. 10.1177/026988110401800308, 15358981.
9. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004, 65(Suppl 18):47-56.
10. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267. 10.2165/00023210-200418040-00005, 15015905.
11. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63:763-771.
12. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60:681-690. 10.1001/archpsyc.60.7.681, 12860772.
13. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003, 61:123-136. 10.1016/S0920-9964(03)00050-1, 12729864.
14. McEvoy J, Daniel D, Carson WJ, McQuade R, Marcus R. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007, 41(11):895-905. 10.1016/j.jpsychires.2007.05.002, 17631314.
15. Cutler A, Marcus R, Hardy S, O'Donnell A, Carson B, McQuade B. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrums 2006, 11:691-702.
16. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003, 6:325-337. 10.1017/S1461145703003651, 14609439.
17. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003, 64:1048-1056. 10.4088/JCP.v64n0910, 14628980.
18. Guy W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76-338 1976, 218-222. Rockville, MD: National Institute of Mental Health.
19. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
20. World Health Organization WHOQoL Study Protocol. WHO (MNH7PSF/93.9) 1993, Geneva, Switzerland: WHO, World Health Organization.
21. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006, 84:77-89. 10.1016/j.schres.2005.12.857, 16483745.
22. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000, 18:106-124.
23. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009, 65:510-517. 10.1016/j.biopsych.2008.07.033, 18986646.
24. Wolf J, Janssen F, Lublin H, Salokangas RK, Allain H, Smeraldi E, Bernardo M, Millar H, Pans M, Adelbrecht C, Laughton J, Werner C, Maier W. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007, 23:2313-2323. 10.1185/030079907X225448, 17706003.
25. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007, 22:433-443. 10.1016/j.eurpsy.2007.03.002, 17555947.
26. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 2004, 27:596-601. 10.2337/diacare.27.2.596, 14747245, American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity.
27. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
28. De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007, 33:823-830. 10.1093/schbul/sbl037, 2526132, 16940338.
29. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007, 27:639-661. 10.1097/jcp.0b013e31815ac4e5, 18004132.
30. Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, Kuo Lin W. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007, 68:1218-1225. 10.4088/JCP.v68n0808, 17854246.